OncoMatch/Clinical Trials/NCT06767813
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Is NCT06767813 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TQB2868 and Gemcitabine for pancreatic neoplasms.
Treatment: TQB2868 · Gemcitabine · Albumin paclitaxel · Anlotinib capsules — To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Exception: Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
Lab requirements
Blood counts
Normal major organ function
Kidney function
Normal major organ function
Liver function
Normal major organ function
Normal major organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify